文献速递肥胖与代谢综合征

中国肥胖症:现状进展与未来展望

Obesity in China: current progress and future prospects.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-12-10

本文剖析中国超重与肥胖患病率持续上升带来的健康和经济负担,综述公共卫生政策、临床研究与实践进展。自2021年起我国新增五种GLP-1受体激动剂获批用于体重管理,但诊断标准、国家量化目标及药物治疗算法仍存挑战,呼吁构建以人为本的整合照护体系。

要点

  • 中国超重与肥胖患病率近十年持续上升,健康与经济后果加重
  • 2021年以来五种GLP-1受体激动剂在华获批体重管理,拓宽治疗选择
  • 现有诊断标准未充分捕捉表型与心血管代谢异质性,亟待完善

核心结论

  • 中国肥胖防控在政策、指南与多部门协作方面取得进展,但诊断标准、国家量化目标和药物治疗算法等挑战可能削弱持续成效。

研究设计与样本

  • 本文为Personal View类型文章,批判性审视中国肥胖领域在公共卫生与政策、临床研究及实践方面的近期进展与新兴挑战。

主要发现

  • 中国超重与肥胖患病率近十年持续上升,健康与经济后果日益加重。
  • 自2021年以来,利拉鲁肽、贝那鲁肽、司美格鲁肽、替尔泊肽和玛仕度肽五种GLP-1受体激动剂在中国获批用于体重管理。
  • 现有肥胖诊断标准存在局限,未能充分反映表型与心血管代谢异质性。
  • 缺乏可量化、可操作、可问责的国家目标,削弱治理与评估。
  • 缺乏循证肥胖药物治疗算法,可能导致过度依赖药物并忽视社会经济、环境和行为决定因素。

临床怎么用

  • 应重视生活方式干预与药物以外社会经济、环境和行为因素在肥胖管理中的作用。
  • 需建立以人为本的整合系统,将全人肥胖照护嵌入行星健康框架,提供预防、治疗与长期支持的连贯服务。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence of overweight and obesity in China has continued to increase over the last decade, with mounting health and economic consequences. In this Personal View, we critically examine recent advances and identify current and emerging challenges in obesity across public health and policy, clinical research, and practice. National policy frameworks, technical health and nutrition guidelines, and multisectoral collaboration have elevated obesity on the public agenda. Evidence supporting lifestyle interventions and medications for obesity continues to accumulate. Since 2021, five additional GLP-1 receptor agonists (including liraglutide, beinaglutide, semaglutide, tirzepatide, and mazdutide) have been approved in China for weight management, broadening therapeutic choices and initiating a transformation in obesity care. Nevertheless, several key challenges remain which can undermine the sustained impact of the progress. These include limitations in existing diagnostic criteria for obesity which captures phenotypic and cardiometabolic heterogeneity; limited availability of quantifiable, actionable, and accountable national targets which weakens governance and evaluation; and a scarcity of evidence-based algorithms for obesity pharmacotherapy, which risks over-reliance on medication and diverts attention from socioeconomic, environmental, and behavioural determinants. We call for people-centred, integrated systems that embed whole-person obesity care within a planetary health framework and deliver a coherent continuum of prevention, treatment, and long-term support.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Pan XF, Fang ZZ, Zhang L, et al. Obesity in China: current progress and future prospects. Lancet Diabetes Endocrinol. 2025. PMID: 41389801. doi:10.1016/S2213-8587(25)00357-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。